Skip to main content

Table 1 Baseline characteristics of patients in the training, internal validation, and external validation cohorts

From: Computer-assisted quantification of tumor-associated collagen signatures to improve the prognosis prediction of breast cancer

Characteristics

Fuzhou training cohort (355)

Fuzhou internal validation cohort (334)

Harbin external validation cohort (253)

Total cohort (942)

Age

 ≤50

199 (56.1%)

194 (58.1%)

136 (53.8%)

529 (56.2%)

 >50

156 (43.9%)

140 (41.9%)

117 (46.2%)

413 (43.8%)

Molecular subtype

 Luminal A

75 (21.1%)

59 (17.7%)

69 (27.3%)

203 (21.5%)

 Luminal B

161 (45.4%)

145 (43.4%)

97 (38.3%)

403 (42.8%)

 HER2-enriched

64 (18.0%)

75 (22.5%)

48 (19.0%)

187 (19.9%)

 Triple negative

55 (15.5%)

55 (16.5%)

39 (15.4%)

149 (15.8%)

Tumor size

 ≤2cm

147 (41.4%)

134 (40.1%)

143 (56.5%)

424 (45.0%)

 2–5cm

187 (52.7%)

174 (52.1%)

107 (42.3%)

468 (49.7%)

 >5cm

21 (5.9%)

26 (7.8%)

3 (1.2%)

50 (5.3%)

Nodal status

 0

180 (50.7%)

169 (50.6%)

117 (46.3%)

466 (49.5%)

 1–3

74 (20.8%)

81 (24.3%)

75 (29.6%)

230 (24.4%)

 ≥4

101 (28.5%)

84 (25.1%)

61 (24.1%)

246 (26.1%)

Clinical stage

 I

96 (27.0%)

83 (24.9%)

74 (29.3%)

253 (26.9%)

 II

156 (43.9%)

161 (48.2%)

117 (46.2%)

434 (46.1%)

 III

103 (29.1%)

90 (26.9%)

62 (24.5%)

255 (27.0%)

Histological grade

 G1

56 (15.8%)

56 (16.8%)

11 (4.4%)

123 (13.1%)

 G2

194 (54.6%)

176 (52.7%)

202 (79.8%)

572 (60.7%)

 G3

105 (29.6%)

102 (30.5%)

40 (15.8%)

247 (26.2%)

ER

 Negative

119 (33.5%)

130 (38.9%)

87 (34.4%)

336 (35.7%)

 Positive

236 (66.5%)

204 (61.1%)

166 (65.6%)

606 (64.3%)

PR

 Negative

152 (42.8%)

155 (46.4%)

108 (42.7%)

415 (44.1%)

 Positive

203 (57.2%)

179 (53.6%)

145 (57.3%)

527 (55.9%)

HER2

 Negative

243 (68.5%)

213 (63.8%)

171 (67.6%)

627 (66.6%)

 Positive

112 (31.5%)

121 (36.2%)

82 (32.4%)

315 (33.4%)

Chemotherapy

 No

28 (7.9%)

28 (8.4%)

27 (10.7%)

83 (8.8%)

 Yes

327 (92.1%)

306 (91.6%)

226 (89.3%)

859 (91.2%)

Endocrine therapy

 No

135 (38.0%)

140 (41.9%)

133 (52.6%)

408 (43.3%)

 Yes

220 (62.0%)

194 (58.1%)

120 (47.4%)

534 (56.7%)

Radiation therapy

 No

234 (65.9%)

232 (69.5%)

195 (77.1%)

661 (70.2%)

 Yes

121 (34.1%)

102 (30.5%)

58 (22.9%)

281 (29.8%)

Targeted therapy

 No

331 (93.2%)

311 (93.1%)

228 (90.1%)

870 (92.4%)

 Yes

24 (6.8%)

23 (6.9%)

25 (9.9%)

72 (7.6%)

  1. Note: ER, estrogen receptor; PR, progesterone receptor